Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...

Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...

Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. ("Halozyme") on behalf of the company's shareholders. The investigation seeks to determine whether Halozyme and/or the ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $62.3 which represents a slight increase of $1.76 or 2.91% from the prior close of $60.54. The stock opened at $61.02 ...

Halozyme announces US FDA approval of Roche's Tecentriq Hybreza with Enhanze for multiple types of cancer: San Diego Saturday, September 14, 2024, 12:00 Hrs [IST] Halozyme Therape ...

Trialbee, the global leader in technology-driven patient recruitment for clinical trials, is thrilled to announce the appointment of John Murray to its Advisory Board. With a distinguished career ...